Abcellera Biologics Inc (ABCL)
$5.26
$0.02
(0.38%)
As on 15-Jun-2026 16:28EDT
Market cap
$1,600 Mln
Revenue (TTM)
$79 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
5.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
305,375,393
6 Years Aggregate
CFO
$507.02 Mln
EBITDA
$255.31 Mln
Net Profit
$126.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
| 53.8 | 19.5 | 50.7 | 64.4 | -10.7 | -26.5 | -- |
|
BSE Sensex*
| -9.3 | 2.1 | 3.0 | -5.3 | 6.9 | 7.8 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
| 16.7 | -43.6 | -29.2 | -64.5 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
5.3 | 1,600.2 | 79.2 | -144.0 | -238.0 | -15.1 | -- | 1.7 |
| 16.0 | 2,034.5 | 298.3 | 298.2 | 47.7 | 63.9 | 7.3 | 3.6 | |
| 5.6 | 304.4 | 0.0 | -35.1 | 125,261.6 | -71 | -- | 6.4 | |
| 5.9 | 51.6 | 0.1 | -10.4 | -20,782.3 | -92.2 | -- | 28.3 | |
| 0.2 | 9.5 | 0.1 | -25.3 | -20,363.0 | -22.2 | -- | 0.1 | |
| 9.2 | 312.6 | 51.0 | -8.4 | -13.3 | -- | -- | 8.3 | |
| 1.5 | 5.0 | 663.9 | -9.9 | -1.5 | -86 | -- | 0.7 | |
| 1.3 | 158.1 | 1.8 | -68.4 | -3,447.7 | -241.8 | -- | 4.4 | |
| 52.4 | 5,036.3 | 0.0 | -383.2 | -- | -40.4 | -- | 3.8 | |
| 0.1 | 95.4 | 27.5 | -101.6 | -167.9 | -60.6 | -- | 0.3 |
Shareholding Pattern
View DetailsAbout Abcellera Biologics Inc (ABCL)
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat... moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Read more
-
CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
-
CEO, President & Chairperson
Dr. Carl L.G. Hansen Ph.D.
-
Headquarters
Vancouver, BC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Abcellera Biologics Inc (ABCL)
What is the current share price of Abcellera Biologics Inc (ABCL) Today?
The share price of Abcellera Biologics Inc (ABCL) is $5.26 (NASDAQ) as of 15-Jun-2026 16:28 EDT. Abcellera Biologics Inc (ABCL) has given a return of -10.71% in the last 3 years.
What is the current PB & PE ratio of Abcellera Biologics Inc (ABCL)?
Since, TTM earnings of Abcellera Biologics Inc (ABCL) is negative, P/E ratio is not available.
The P/B ratio of Abcellera Biologics Inc (ABCL) is 1.71 times as on 12-Jun-2026, a 58 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.98
|
1.06
|
|
2024
|
-5.29
|
0.82
|
|
2023
|
-11.27
|
1.43
|
|
2022
|
20.13
|
2.59
|
|
2021
|
-2,057.00
|
4.43
|
What is the 52 Week High and Low of Abcellera Biologics Inc (ABCL)?
The 52-week high and low of Abcellera Biologics Inc (ABCL) are Rs 6.79 and Rs 2.75 as of 16-Jun-2026.
What is the market cap of Abcellera Biologics Inc (ABCL)?
Abcellera Biologics Inc (ABCL) has a market capitalisation of $ 1,600 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Abcellera Biologics Inc (ABCL)?
Before investing in Abcellera Biologics Inc (ABCL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.